Time to Strategy Failure and Treatment Beyond Progression in Pretreated Metastatic Renal Cell Carcinoma Patients Receiving Nivolumab: Post-Hoc Analysis of the Meet-URO 15 Study
Frontiers in oncology（2024）
关键词
metastatic renal cell carcinoma,immunotherapy,immune checkpoint inhibitors,nivolumab,treatment beyond progression,time to strategy failure,time to treatment failure
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要